Studies have shown that CD44 cleavage is widespread across various malignancies, with ectodomain cleavage detected in 58% of gliomas, 67% of breast carcinomas, 90% of colon carcinomas, and other cancers, including non-small cell lung carcinoma and ovarian carcinoma. This evidence concerns the gene CD44 and ovarian carcinoma.